XML 53 R35.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer concentration risk | 12 Months Ended
--- | ---
Dec. 31, 2021 | Jan. 01, 2021 | Jan. 03, 2020
Ipsen Pharma SAS | Sales revenue, net |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 21.00% | 15.00% | 16.00%
Ipsen Pharma SAS | Accounts Receivable |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 50.00% | 23.00% |
Affiliates of CVS Health Corporation | Sales revenue, net |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 14.00% | 14.00% | 15.00%
Affiliates of CVS Health Corporation | Accounts Receivable |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 9.00% | 11.00% |
Affiliates of McKesson Corporation | Sales revenue, net |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 14.00% | 12.00% | 12.00%
Affiliates of McKesson Corporation | Accounts Receivable |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 10.00% | 12.00% |
Affiliates of AmerisourceBergen Corporation | Sales revenue, net |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 14.00% | 11.00% | 11.00%
Affiliates of AmerisourceBergen Corporation | Accounts Receivable |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 11.00% | 11.00% |
Affiliates of Optum Specialty Pharmacy | Sales revenue, net |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 8.00% | 11.00% | 13.00%
Takeda Pharmaceutical Company Limited | Accounts Receivable |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |
Percent of total revenues | 2.00% | 10.00% |

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=exel_IpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_TakedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |